SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending after reporting robust earnings and strong guidance driven by its booming data center and AI segments, yet community discussion is polarized between long-term bullish conviction in its AI leadership and concerns over the muted stock reaction, high valuation, and options expiring worthless amid perceived market manipulation.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as the community celebrates a significant earnings and revenue beat, fueling expectations of continued growth driven by the Alani Nu acquisition and expanding PepsiCo partnership. Investors are actively discussing the potential for the stock to be "Monster 2.0" and reach new highs as it gains substantial shelf space.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is experiencing a sharp pullback following a significant earnings miss, drawing community criticism regarding execution and financial forecasting. Despite the immediate negative sentiment driving the sell-off, many investors are actively discussing it as a potential buying opportunity given the company's long-term position in the critical and growing energy storage sector, particularly for data centers.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending following a strong earnings report, marked by a significant EPS beat and substantial share repurchases, which is fueling widespread community speculation about a potential buyout and updates on its AUR200 pipeline.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending upward after reporting a strong Q4 earnings beat and securing a spot on the Missile Defense Agency's massive SHIELD contract, driving community excitement about a potential short squeeze despite continued scrutiny over its valuation and the nascent stage of the quantum computing industry.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending due to anticipation surrounding its upcoming earnings report, following the milestone of opening its 30,000th store and a strategic shift towards premium offerings after the conclusion of regional price wars. The community is actively discussing potential margin expansion, the chairman's increased personal stake, and the ongoing speculation about a major exchange relisting, often tempered by historical skepticism regarding immediate price action.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. (QBTS) is actively debated following recent partnerships with defense and federal agencies, driving conversation around its competitive dual-platform approach and potential for strong financial results within the highly speculative, yet promising, quantum computing sector.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending after its earnings report delivered a revenue and EPS beat, but its weaker-than-expected Q1 guidance triggered a significant share price decline and a Loop Capital downgrade. Community sentiment is split, with many investors decrying perceived management missteps and market manipulation, while others view the substantial dip as an attractive entry point for a fundamentally sound, oversold company.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is surging as robust financial results, including a boosted profit outlook and plans for significant shareholder returns, drive community enthusiasm for its remarkable turnaround and diversified growth in defense, SMRs, and civil aerospace.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending due to its ANKTIVA's expanded European access and global approvals for bladder cancer, coupled with strong clinical data and 700% year-over-year revenue growth. The community is buzzing about a recent significant pullback, debating whether it's a buying opportunity or a "bear trap" for shorts, given the high short interest and the founder's reaffirmed majority control.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BTIG reiterated $VRDN Buy/$61. 
$ARGX $IMVT $SLRN $AMGN  
BTIG said: 
Enrollment in the Phase 3 trials REVEAL-1/2 of VRDN-003 (SC autoinjector IGF-1R mAb) has completed, with 132 patients enrolled in REVEAL-1 and 204 patients enrolled in REVEAL-2 (initial target enrollment of 117 and 195, respectively). 67% of enrollment in REVEAL-1 (active TED) and 56% of that in REVEAL-2 (chronic TED) came from the US. 
 
Topline data for these studies remain on track for 1H26 and we continue to view the readout as reasonably de-risked as VRDN-003 shares the same binding domains as veligrotug. 
 
We also expect payors to prefer an SC administered option, and we are not aware of any other publicly announced late-stage development efforts of an SC autoinjector IGF-1R Tx option. 
 
BTIG went on to say:

Stifel reitd $VRDN Buy-$41 after hosting CEO Steve Mahoney/CBO Shan Wu 2discuss Veligrotug clinical data in TED/path towards commercialization—ongoing VRDN-003 Ph3 program—FcRn franchise 
$ARGX $IMVT $SLRN $AMGN 
 
&quot;Bottom line, $VRDN continues to execute across their pipeline and remains well-positioned to transition into a commercial company next year. 
 
Amid broader negative biotech sentiment, $VRDN is well-capitalized with ~$720MM in cash as of 4Q24 
following two positive Ph3 studies for lead next-gen IGF1R mAb Veligrotug in TED, a still nascent, large commercial market. 
 
Management emphasized that Veligrotug BLA filing is on track for 2H25 and they have built a strong commercial strategy based on the differentiated product profile. 
 
Meanwhile, topline data for subcu VRDN-003 are expected 1H26 and should drive further growth within 
the broader TED market. 
 
Finally, management emphasized the significant optionality within their FcRn portfolio -- seeking to improve upon the success of efgartigimod.&quot;

StockTwits Web

Viridian Therapeutics Inc

Argenx

Immunovant Inc

Acelyrin Inc

AMGEN Inc.

Quantumup

Jefferies reiterated $VRDN at a Buy-$44, and said that $RHHBY&#39;s results remove key comp pressure and position &#39;003 as the leading Q4W+ SubQ therapy for TED 
after Roche&#39;s mixed Phase 3 results for its IL-6mAb Satralizumab in thyroid eye diseases—one pivotal trial didn&#39;t hit the primary endpoint while the other showed efficacy meaningfully weaker than $VRDN&#39;s Veligrotug.

  
BTIG said: 
Enrollment in the Phase 3 trials REVEAL-1/2 of VRDN-003 (SC autoinjector IGF-1R mAb) has completed, with 132 patients enrolled in REVEAL-1 and 204 patients enrolled in REVEAL-2 (initial target enrollment of 117 and 195, respectively). 67% of enrollment in REVEAL-1 (active TED) and 56% of that in REVEAL-2 (chronic TED) came from the US. 
 
Topline data for these studies remain on track for 1H26 and we continue to view the readout as reasonably de-risked as VRDN-003 shares the same binding domains as veligrotug. 
 
We also expect payors to prefer an SC administered option, and we are not aware of any other publicly announced late-stage development efforts of an SC autoinjector IGF-1R Tx option. 
 
BTIG went on to say: